Maridea Wealth Management LLC Makes New $649,000 Investment in Thermo Fisher Scientific Inc. $TMO

Maridea Wealth Management LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,294 shares of the medical research company’s stock, valued at approximately $649,000.

Other hedge funds also recently added to or reduced their stakes in the company. Bridgewater Advisors Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter valued at about $1,366,000. BIP Wealth LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $308,000. Compound Global Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $50,000. Trifecta Capital Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $6,017,000. Finally, Everett Harris & Co. CA acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at approximately $7,916,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TMO shares. Piper Sandler boosted their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $619.41.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,053 shares of company stock valued at $30,643,589 in the last quarter. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $588.17 on Monday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a PEG ratio of 2.39 and a beta of 0.84. The stock has a 50-day simple moving average of $529.37 and a two-hundred day simple moving average of $508.75.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.